甲型流感IFA熒光玻片

廣州健侖生物科技有限公司

廣州健侖長(zhǎng)期供應(yīng)各種流感檢測(cè)試劑，包括進(jìn)口和國(guó)產(chǎn)的品牌，主要包括日本富士瑞必歐、日本生研、美國(guó)BD、美國(guó)NovaBios、美國(guó)binaxNOW、英國(guó)clearview、凱必利、廣州創(chuàng)侖等主流品牌。

甲型流感IFA熒光玻片

我司還提供其它進(jìn)口或國(guó)產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國(guó)SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

我們很高興發(fā)現(xiàn)一個(gè)重要的分子通路，ERK通路，它決定是否一個(gè)成體細(xì)胞能夠重編程并幫助再生過程。操縱這一機(jī)制能促進(jìn)定向治療增強(qiáng)人細(xì)胞的再生可能性。
ERK通路是蛋白質(zhì)從細(xì)胞表面?zhèn)鬟f信號(hào)到包含細(xì)胞遺傳物質(zhì)的細(xì)胞核中的一種方式。進(jìn)一步研究將集中在了解這一重要途徑在斷肢再生中是如何調(diào)節(jié)的，以及相關(guān)過程中的其他分子。
美國(guó)斯隆-凱特琳研究所等處的研究人員創(chuàng)建了一種多能干細(xì)胞基因組編輯平臺(tái)：iCRISPR，這一平臺(tái)能快速，高效的敲除干細(xì)胞中的基因，而且還能在干細(xì)胞分化過程中，進(jìn)行階段特異性的基因敲除，這將在人類疾病復(fù)雜病理研究中大放異彩。相關(guān)文章發(fā)表于2014年6月12日的《Cell Stem Cell》雜志上。
人體多能干細(xì)胞(hPSCs)不僅能被用于臨床的再生研究應(yīng)用中，而且也能作為解析復(fù)雜性狀和特征的*平臺(tái)，闡明其背后的基因和分子途徑。為了實(shí)現(xiàn)這一目的，科學(xué)家們開發(fā)了多種遺傳操控方法，但是這些方法依然存在各種問題，我們需要快速，具有可操控性的生物學(xué)手段。
在這篇文章中，研究人員就利用CRISPR和TALEN，這兩種備受關(guān)注的基因組編輯技術(shù)，研發(fā)出了一種人類多能干細(xì)胞基因組編輯平臺(tái)。研究人員將這一平臺(tái)稱為iCRISPR。
iCRISPR能用于基因功能喪失研究中，快速，高效的敲除人體多能干細(xì)胞中的等位基因，也可以針對(duì)一些精確的疾病模型，通過特定的核苷酸變換，進(jìn)行多能干細(xì)胞純合體敲除。
通過進(jìn)一步實(shí)驗(yàn)，研究人員驗(yàn)證了雙重和三重基因敲除hPSC細(xì)胞系一步法的有效性，同時(shí)也證明了在多能干細(xì)胞分化過程中能進(jìn)行階段特異性誘導(dǎo)基因敲除，這對(duì)于發(fā)育生物學(xué)研究來說意義重大。
由此研究人員指出，iCRISPR平臺(tái)尤其適合用于解析人類疾病研究中的復(fù)雜遺傳相互作用，以及多效性基因功能，這將有助于進(jìn)行人體多能干細(xì)胞高通量遺傳分析。

We are happy to find an important molecular pathway, the ERK pathway, that determines whether an adult cell can reprogram and help regenerate the process. Manipulating this mechanism can promote targeted therapy to enhance the regenerative potential of human cells.
The ERK pathway is one way in which proteins transfer signals from the cell surface into the nucleus containing cytogenetic material. Further research will focus on understanding how this important pathway is regulated in limb amputation and other molecules involved in the process.
Researchers at the U.S.-based Sloan-Caitlin Institute have created iCRISPR, a pluripotent stem cell genomics editing platform that rapidly and efficiently knocks out genes in stem cells and helps them differentiate stem cells during stem cell differentiation, Performing stage-specific knockouts will shine in the complex pathology of human disease. The article appeared in the June 12, 2014 issue of Cell Stem Cell.
Not only can human pluripotent stem cells (hPSCs) be used in clinical regenerative research applications, but also as a unique platform for analyzing complex traits and traits, elucidating the underlying genetic and molecular pathways. To achieve this goal, scientists have developed a variety of genetic manipulation methods, but there are still a variety of problems with these methods, and we need fast, manipulative biological tools.
In this article, researchers developed a human pluripotent stem cell genome editing platform using two well-regarded genome editing technologies, CRISPR and TALEN. The researchers call this platform iCRISPR.
iCRISPR can be used in gene loss studies to rapidly and efficiently knock out alleles in pluripotent human pluripotent stem cells and to target specific models of disease through specific nucleotide transforms for pluripotent stem cell homozygous knocking except.
Through further experiments, the researchers validated the one-step efficacy of double and triple knockout hPSC cell lines, and also demonstrated that stage-specific induction of gene knockdown during pluripotent stem cell differentiation can be performed in developmental biology Meaningful.
As a result, the researchers noted that the iCRISPR platform is particularly well-suited for the analysis of complex genetic interactions in human disease research and pleiotropic gene functions that will facilitate high-throughput genetic analysis of human pluripotent stem cells.